Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Pharmas Display Defensive Mettle But Headwinds Mount

Aug 22 2022

• By Jessica Merrill

Money Boat — • Source: Shutterstock

Related Content

The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’

Nov 06 2021

As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

Aug 04 2022

Pharma Braces For Potential Landmark Moment For US Drug Price Controls

Aug 02 2022

AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal

Jul 29 2022

Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business

Jul 28 2022

Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers

Jul 28 2022

Bristol’s New Products Meet Early Launch Expectations

Jul 28 2022

Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

Aug 16 2022

The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall

Apr 04 2022

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Seagen Inc.

Johnson & Johnson

Pfizer Inc.

Eli Lilly and Company

Additional Topics

United States Sales & Earnings Commercial Companies Growth Market Intelligence BioPharmaceutical

More from Growth

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window